Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age - PubMed
Review
Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age
D Lindhout et al. Epilepsia. 1994.
Abstract
Exposure to antiepileptic drug (AED) treatment in utero occurs in 1 of every 250 newborns. The absolute risk of major malformations in these infants is about 7-10%, approximately 3-5% higher than in the general population. Specific risk factors include high maternal daily dosage or serum concentrations of AED, low folate levels, polytherapy, and generalized seizures during pregnancy. Adverse pregnancy outcomes, including congenital heart malformations, facial clefts, spina bifida aperta, hypospadias, growth retardation, and psychomotor and mental retardation, are associated with, although not necessarily caused by, AED exposure. Specific cognitive defects, hypertelorism, and nail hypoplasia can be causally related to specific AED exposures. To prevent teratogenic side effects, the prospective mother should be treated with AEDs only when absolutely necessary. Monotherapy with the AED that is most effective in the lowest possible daily dose (divided into at least two or three administrations) should be prescribed. High-dose folate supplementation (4-5 mg/day) reduces the risk of a neural tube defect in a child whose sibling had such a defect, but its impact on the specific teratogenic risks of AEDs is unknown. A substantial proportion of fetal malformations may be secondarily prevented by prenatal diagnosis, consisting of a fetal structural ultrasound examination at weeks 18 and 20 of gestation and, with VPA or CBZ administration, an alpha 1-fetoprotein analysis of amniotic fluid at week 16. Determination of a specific defect prevention strategy depends largely on parental attitudes toward prenatal diagnosis and termination of pregnancy, which should be discussed before conception.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Pregnancy and the risk of teratogenicity.
Lindhout D, Omtzigt JG. Lindhout D, et al. Epilepsia. 1992;33 Suppl 4:S41-8. doi: 10.1111/j.1528-1157.1992.tb06226.x. Epilepsia. 1992. PMID: 1425493 Review.
-
Oguni M, Osawa M. Oguni M, et al. Epilepsia. 2004;45 Suppl 8:37-41. doi: 10.1111/j.0013-9580.2004.458008.x. Epilepsia. 2004. PMID: 15610193 Review.
-
Management of epilepsy during pregnancy.
Battino D, Tomson T. Battino D, et al. Drugs. 2007;67(18):2727-46. doi: 10.2165/00003495-200767180-00007. Drugs. 2007. PMID: 18062721 Review.
-
Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D. Samrén EB, et al. Epilepsia. 1997 Sep;38(9):981-90. doi: 10.1111/j.1528-1157.1997.tb01480.x. Epilepsia. 1997. PMID: 9579936
Cited by
-
Burja S, Rakovec-Felser Z, Treiber M, Hajdinjak D, Gajsek-Marchetti M. Burja S, et al. Wien Klin Wochenschr. 2006;118 Suppl 2:12-6. doi: 10.1007/s00508-006-0539-8. Wien Klin Wochenschr. 2006. PMID: 16817037
-
Quattrini A, Ortenzi A, Paggi A, Foschi N, Quattrini C. Quattrini A, et al. Ital J Neurol Sci. 1996 Dec;17(6):441. doi: 10.1007/BF01997721. Ital J Neurol Sci. 1996. PMID: 8978453 No abstract available.
-
Neurological teratogenic effects of antiepileptic drugs during pregnancy.
Nie Q, Su B, Wei J. Nie Q, et al. Exp Ther Med. 2016 Oct;12(4):2400-2404. doi: 10.3892/etm.2016.3628. Epub 2016 Aug 29. Exp Ther Med. 2016. PMID: 27698740 Free PMC article.
-
Parial S. Parial S. Indian J Psychiatry. 2015 Jul;57(Suppl 2):S252-63. doi: 10.4103/0019-5545.161488. Indian J Psychiatry. 2015. PMID: 26330643 Free PMC article. Review.
-
Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, Wlodarczyk B, White HS, Bialer M. Isoherranen N, et al. Br J Pharmacol. 2003 Jun;139(4):755-64. doi: 10.1038/sj.bjp.0705301. Br J Pharmacol. 2003. PMID: 12812999 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical